Drug Effects Questionnaire

Last updated

The Drug Effects Questionnaire (DEQ), also known as the Drug Effect Questionnaire, is a psychometric questionnaire which is used to assess the subjective effects of psychoactive drugs. [1] [2] [3] It is a visual analogue scale (VAS). [1] [2] The questionnaire is used to quickly measure whether a subject feels the drug, "feels high", likes or dislikes the effects, and whether they want more of the drug. [1] [2] The format of the DEQ is often modified and varies widely across studies, such that it cannot easily be regarded as a standardized instrument. [1] The DEQ has notably been used to assess the subjective effects of serotonergic psychedelics in clinical trials. [1] [4] It was first described in the literature by 1961. [2] [5]

See also

References

  1. 1 2 3 4 5 Hovmand OR, Poulsen ED, Arnfred S (January 2024). "Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics". J Psychopharmacol. 38 (1): 19–32. doi:10.1177/02698811231200019. PMC   10851631 . PMID   37969069.
  2. 1 2 3 4 de Wit, Harriet (15 February 2013). "Measuring Direct Effects of Drugs of Abuse in Humans". The Wiley‐Blackwell Handbook of Addiction Psychopharmacology. Wiley. p. 257–280. doi:10.1002/9781118384404.ch10. ISBN   978-1-119-97826-8 . Retrieved 12 October 2025. 3.1.1.1 DRUG EFFECT QUESTIONNAIRE. The Drug Effect Questionnaire (DEQ; Fraser et al., 1961) consists of four or five visual analog rating scales on which participants answer questions about the drug effect, from "not at all" to "very much." The questions are typically: "Feel drug" (do you feel a drug effect?), "Like drug" (do you like the effects you feel?), "High" (are you "high"?) and "More" (do you want more of the drug you just received?). Sometimes investigators also include a scale for "Dislike," because of the potential ambiguity in the "Like drug" question and because it is possible to both like and dislike current drug effects at the same time.
  3. ↑ Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS (May 2013). "The drug effects questionnaire: psychometric support across three drug types". Psychopharmacology (Berl). 227 (1): 177–192. doi:10.1007/s00213-012-2954-z. PMC   3624068 . PMID   23271193.
  4. ↑ Ludbrook G, Bryson N, Taylor B, Hocevar-Trnka J, Johnson MW, Hirman J, Morrish G, Alexander R, Pollack M (2025). "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study". J Clin Psychopharmacol. 45 (5): 441–453. doi:10.1097/JCP.0000000000002047. PMC   12379775 . PMID   40685873.
  5. ↑ Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (September 1961). "Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test". J Pharmacol Exp Ther. 133: 371–387. PMID   13701509.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.